![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
BRAF Mutation and Cancer - Johns Hopkins Medicine
What does it mean if I have a BRAF mutation? Knowing that you have a BRAF mutation will help your oncologist select appropriate cancer therapies. The presence of a BRAF mutation gives your doctors clues about: Best medicines to target the cancer cells; How fast the tumor might grow and how large it might get
BRAF V600E -mutant metastatic NSCLC: disease overview and ...
2024年4月16日 · In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF...
BRAF (gene) - Wikipedia
More than 30 mutations of the BRAF gene associated with human cancers have been identified. The frequency of BRAF mutations varies widely in human cancers, from more than 80% in melanomas and nevi, to as little as 0–18% in other tumors, such as 1–3% in lung cancers and 5% in colorectal cancer. [28]
BRAF Mutation in Thyroid Cancer: Prevalence, Treatment & More
2023年8月10日 · Some thyroid cancers have mutations in a gene that codes for a protein called BRAF. This mutation may affect the outlook for people who have thyroid cancer, although research remains mixed....
BRAF Mutation: Cancer Types, Testing, Treatment - Verywell Health
2024年6月23日 · BRAF mutations are DNA changes in some cancer cells that can be treated with newer targeted therapies. BRAF mutations are found in roughly half of melanomas. Medications that target these mutations have significantly improved the survival rates of metastatic melanoma.
Emerging BRAF Mutations in Cancer Progression and Their ...
Gene mutations can induce cellular alteration and malignant transformation. Development of many types of cancer is associated with mutations in the B-raf proto-oncogene (BRAF) gene.
BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment ...
In this review, we summarized the BRAF mutation types, the diagnostic challenges that BRAF mutations present, the strategies to treatment for BRAF-mutated NSCLC, and resistance mechanisms of BRAF-targeted therapy.
BRAF — a tumour-agnostic drug target with lineage-specific ...
2024年1月26日 · In this Review, we describe the biochemical basis for oncogenic BRAF-induced activation of MAPK signalling and pan-cancer and lineage-specific mechanisms of intrinsic, adaptive and acquired...